Phenobarbitone pharmacokinetics

Mamiya, K., Hadama, A., Yukawa, E., Ieiri, I., Otsubo, K., Ninomiya, H., Tashiro, N., and Higuchi, S. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy Analysis by population pharmacokinetics. European Journal of Clinical Pharmacology 2000 55 821-825. 

Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr Scand Suppl 1989 350 95-8. 

Amabeoku GJ, Chikuni O, Akino C, Mutetwa S. Pharmacokinetic interaction of single doses of quinine and carbamazepine, phenobarbitone and phenytoin in healthy volunteers. East Afr Med J 1993 70(2) 90-3. 

Hooper WD, Kavanagh MC, Herkes GK, Eadie Ml. Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin BrJ Clin Pharmacol (1991) 31,171-4. 

Tartara A, Galimberti CA, Manni R, Morini R, Limido G, Gatti G, Bartoli A, Strad G, Peruc-ca E. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydrojqf-car-bazepine in healthy subjects and in epileptic patients taking phenobarbitone or valproic acid. Br J Clin Pharmacol (1993) 36, 366-8. 

Hooper WD, Eadie MJ, Blakey G Lockton JA, Manun Ebo M. Evaluation of a pharmacokinetic interaction between remaeemide hydrochloride and phenobarbitone in healthy males. Br JCUnPharmacol(2ty0 ) 51,249-55. 

Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady state in healthy subjects. BrJ Clin PharmcKol (2003) 56, 39-45. 

Manlyla R, Mannisto P, Nykanen S, Koponen A, Lamm insivu U. Pharmacokinetic interactions of timolol witii vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol (1983) 24,227-30. 

---